CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal ...

Pfizer delivered a strong Q2 earnings beat, raising FY2025 guidance and demonstrating effective cost-cutting. Learn why PFE ...

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...

FRANKFURT (Reuters) -German biotech firm BioNTech on Monday said that second-quarter revenues more than doubled to 261 ...

Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting ...

BioNTech stock was rising after the drugmaker reported better-than-expected results on Monday. In early trading, the ...

Pfizer says it will appeal the Aug 1 ruling to Britain’s Supreme Court. Read more at straitstimes.com. Read more at ...

Pfizer beats Q2 2025 estimates, raises EPS guidance, boasts a 7%+ dividend yield, yet faces patent and pricing risks. See why ...

Moderna is not asking that courts take the Pfizer-BioNTech COVID-19 vaccine off the market or to stop future sales, in view of the public need for the vaccines. Moderna and Pfizer's vaccines have ...

Moderna sued Pfizer and its German partner BioNTech on Friday, alleging that the rival firms improperly used its foundational technology in developing their coronavirus vaccine. The suit sets up a ...

Moderna is suing Pfizer and BioNTech for infringing patents central to Moderna's mRNA technology platform used to develop the COVID vaccine, the company said in a press release Friday. A widely ...